Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Consun Pharmaceutical GroupCPHGF +9.09%55 Interest Coverage is 334.43 as of Dec. 2025, which is 771% above its 10-year median of 38.39. GuruFocus rates CPHGF with a GF Score™ of 55/100 and a GF Value™ of $0.60 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 687 Drug Manufacturers companies, Consun Pharmaceutical Group ranks better than 87.05% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Consun Pharmaceutical Group's
Operating Income
for the
six
months ended in Dec. 2025 was $90.0 Mil. Consun Pharmaceutical Group's Interest Expense for the
six
months ended in Dec. 2025 was $-0.3 Mil.
Consun Pharmaceutical Group's interest coverage for the quarter that ended in Dec. 2025 was 334.43.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Consun Pharmaceutical Group Ltd has enough cash to cover all of its debt. Its financial situation is stable.
The historical rank and industry rank for Consun Pharmaceutical Group's Interest Coverage or its related term are showing as below:
CPHGF'
s Interest Coverage Range Over the Past 10 Years
Min: 19.54 Med: 38.39 Max: 264.62
Current: 264.62
CPHGF's Interest Coverage is ranked better than 87.05% of 687
companies
in the Drug Manufacturers industry
Industry Median: 12.75
vs CPHGF: 264.62
Consun Pharmaceutical Group (OTCPK:CPHGF) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Consun Pharmaceutical Group Interest Coverage Related Terms
Consun Pharmaceutical Group Interest Coverage Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Consun Pharmaceutical Group Interest Coverage Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Consun Pharmaceutical Group's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Consun Pharmaceutical Group Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Consun Pharmaceutical Group's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Consun Pharmaceutical Group's Interest Coverage falls into.
Consun Pharmaceutical Group Interest Coverage Calculation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Consun Pharmaceutical Group (CPHGF) has a Interest Coverage of 334.43 as of Dec. 2025. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Consun Pharmaceutical Group and its competitors. This is 771% above median its historical median of 38.39. Over the past decade, Consun Pharmaceutical Group's Interest Coverage has ranged from 19.54 to 264.62. According to the industry distribution chart, Consun Pharmaceutical Group ranks #89 out of 687 companies in the Drug Manufacturers industry, placing it in the top 13%.
Is Consun Pharmaceutical Group's Interest Coverage too high?
Consun Pharmaceutical Group's current Interest Coverage of 334.43 is 771% above median its 10-year median of 38.39. Over the past 10 years, this metric has ranged from a low of 19.54 to a high of 264.62. The Drug Manufacturers industry median Interest Coverage is 12.75. Consun Pharmaceutical Group's value of 334.43 is 2523% above this industry median. Based on the distribution chart, Consun Pharmaceutical Group ranks #89 out of 687 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Consun Pharmaceutical Group has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Consun Pharmaceutical Group's Interest Coverage compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Consun Pharmaceutical Group ranks #89 out of 687 companies for Interest Coverage. This places Consun Pharmaceutical Group in the top 13% of its industry — outperforming the majority of peers. The industry median Interest Coverage is 12.75. Consun Pharmaceutical Group's value of 334.43 is 2523% above this benchmark. Historically, Consun Pharmaceutical Group's own Interest Coverage has ranged from 19.54 to 264.62 over the past decade. While the company's 10-year median is 38.39 vs. the industry median of 12.75, Consun Pharmaceutical Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.75, based on 687 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Consun Pharmaceutical Group's current Interest Coverage of 334.43 is 2523% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Consun Pharmaceutical Group and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Consun Pharmaceutical Group's current Interest Coverage is 334.43, which is 771% above median its own 10-year median of 38.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Consun Pharmaceutical Group stock overvalued right now?
Based on GuruFocus' analysis, Consun Pharmaceutical Group (CPHGF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.60, compared to a current price of $1.80 — trading 200% above its estimated fair value. The current Interest Coverage is 334.43, which is 771% above median its 10-year median of 38.39 and 2523% above the Drug Manufacturers industry median of 12.75. Consun Pharmaceutical Group's overall GF Score™ is 55/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Consun Pharmaceutical Group (CPHGF), the current Interest Coverage is 334.43 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Consun Pharmaceutical Group (CPHGF) Overvalued in 2026?
Based on GuruFocus' analysis, Consun Pharmaceutical Group stock appears to be overvalued.
The current stock price of $1.80 is trading 200% above its estimated GF Value™ of $0.60.
GuruFocus considers Consun Pharmaceutical Group to be Significantly Overvalued.
Key valuation signals for CPHGF:
Interest Coverage: 334.43 (771% above median its 10-year median of 38.39)
GF Value™: $0.60 vs. price of $1.80 (200% above fair value)
Industry Position: 2523% above the Drug Manufacturers median (#89 of 687)
No single metric tells the full story. See the CPHGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Consun Pharmaceutical Group Ltd is a biotechnology company with a modern pharmaceutical enterprise that integrates R&D, production, and marketing. The company has two reportable segments: the Consun pharmaceutical segment, which is the key revenue driver, and makes and sells modern Chinese medicines and medical contrast medium, and the Yulin pharmaceutical segment, which manufactures and sells traditional Chinese medicines. Company derives revenue from kidney medicines, contrast mediums, orthopedics medicines, dermatologic medicines, hepatobiliary medicines, medicines for women and children, and others.
55GF Score
Get the complete analysis for CPHGF
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CPHGF has been successfully added to your 
